Abivax SA (ABVX) AI Stock Analysis

Abivax SA is a clinical-stage biotechnology company headquartered in Paris, France. Founded in 2013, the company develops therapies that harness the body's innate regulatory mechanisms to manage and stabilize immune responses in patients with chronic inflammatory diseases. Its lead drug candidate is obefazimod, which is currently advancing through Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. Beyond ulcerative colitis, Abivax continues exploring the therapeutic potential of its platform across a spectrum of other chronic inflammatory diseases to improve long-term outcomes for patients.

Abivax generated $10.8M in revenue in FY2024, up 133.5% from $4.6M in FY2023 and $4.6M in FY2022. Between FY2019 and FY2024, revenue grew at a 5-year CAGR of 457.7%. However, the company remains unprofitable due to heavy clinical development spending. Operating margin was -1602.9% in FY2024, with net income of -$176.2M and R&D expense of $146.5M. In the trailing twelve months ending June 30, 2026, revenue stood at $4.7M with EPS of -$6.08 and an operating margin of -8617.9%. In the latest quarter ending June 30, 2026, quarterly revenue fell 6.8% year-over-year.

As of June 30, 2026, Abivax reported $410.7M in cash and short-term investments and $1.2M in total debt, resulting in net cash of $409.5M. Total assets stood at $462.2M, while shareholders' equity reached $366.3M. The company maintains short-term liquidity with a current ratio of 5.97 and a debt-to-equity ratio of 0.00. In FY2025, capital expenditures were $136,396, while cash burn remained significant, with free cash flow of -$154.7M in FY2024. Over five years, its share count expanded by 375.4%.

At a closing price of $88.13 on October 16, 2026, Abivax had a market capitalization of $7.69B and an enterprise value of $7.90B. The stock traded at an enterprise value to revenue multiple of 157.6x and a price-to-book ratio of 19.5x. By comparison, the median of its US-listed Healthcare peers had a price-to-sales ratio of 4.1x, an EV to EBITDA multiple of 12.0x, and a trailing P/E of 24.6x. Over the past year, ABVX fell 5.1%, while the S&P 500 (SPY) returned 16.8%.

Wall Street sentiment is positive, with 8 Strong Buy and 4 Buy ratings, alongside zero Hold, Sell, or Strong Sell ratings. The mean price target is $163.58, representing an upside of 85.6% from the last close of $88.13. Consensus estimates project full-year revenue of $4.0M and EPS of -$4.19 for the fiscal year ending December 31, 2026. For the next fiscal year, 7 analysts project revenue to reach $71.9M, representing 1695.5% growth. Abivax beat EPS estimates in 1 of the last 4 quarters.

This page is an AI-written research summary of Abivax SA (ABVX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ABVX income statement, ABVX balance sheet, ABVX key metrics, ABVX analyst forecast, ABVX chart. See the ABVX stock overview for the latest quote and news.